SCHEMBL3500966

SCHEMBL3500966

Cc1cc(NCC(=O)Nc2cc(C)[nH]n2)n[nH]1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPL P05186 2/20 0.57
ALPG P10696 1/20 0.57
CCNA2 P20248 3/20 0.53
CDK2 P24941 3/20 0.53
CCNA1 P78396 3/20 0.53
NPC1 O15118 7/20 0.47
RAB9A P51151 7/20 0.47
ATM Q13315 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.43
CDK7 P50613 1/20 0.43
CCNH P51946 1/20 0.43
MNAT1 P51948 1/20 0.43
TP53 P04637 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
ALDH1A1 P00352 2/20 0.41
GAA P10253 2/20 0.41
LMNA P02545 1/20 0.41
MPI P34949 1/20 0.41
ADORA2A P29274 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3499408 0.85 NPY5R (0.51) ALPLALPGCCNA2CDK2CCNA1
SCHEMBL28413195 0.80 CDK2 (0.62) ALPLCCNA2CDK2CCNA1NPC1
SCHEMBL6341559 0.78 CCNA2 (0.62) ALPLALPGCCNA2CDK2CCNA1
SCHEMBL6349668 0.78 CCNA2 (0.62) ALPLALPGCCNA2CDK2CCNA1
SCHEMBL3499690 0.78 NPY5R (0.55) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL19752036 0.78 ALPL (0.44) ALPLALPGCCNA2CDK2CCNA1
SCHEMBL3498417 0.77 CCNA2 (0.60) ALPLALPGCCNA2CDK2CCNA1
SCHEMBL29972030 0.75 CCNA2 (0.58) ALPLALPGCCNA2CDK2CCNA1
SCHEMBL22311169 0.75 CDK2 (0.64) CCNA2CDK2CCNA1NPC1RAB9A
SCHEMBL22311173 0.74 MEN1 (0.60) CCNA2CDK2CCNA1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144793-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS AC IMMUNE SA (CH) 2010-06-10 US disclosed
US-20100144793-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS AC IMMUNE SA (CH) 2010-06-10 US disclosed
US-20100144793-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS AC IMMUNE SA (CH) 2010-06-10 US disclosed
EP-2121619-A2 COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS AC Immune S.A. (CH) 2009-11-25 EP disclosed
WO-2008061796-A2 COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS AC IMMUNE SA (CH) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144793-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS APP, BACE1, APBA1 ALPL 4530/4885ALPG 4677/4885CCNA2 802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.